The goal of this clinical trial is to learn whether an artificial intelligence (AI) tool called FibroX can help primary care providers better diagnose significant liver fibrosis (≥F2) and clinically significant portal hypertension in adults with metabolic dysfunction-associated steatotic liver disease (MASLD).
The main questions it aims to answer are:
* Can FibroX improve the accuracy of diagnosing significant liver fibrosis (≥F2) and clinically significant portal hypertension compared to usual care?
* Is FibroX easy to use and acceptable to primary care providers in simulated clinical settings?
* Do providers trust FibroX as a decision-support tool?
Researchers will compare FibroX-assisted care to usual care to see if FibroX improves diagnostic accuracy, provider trust, and supports better decision-making.
Participants will:
* Be primary care providers (MDs, DOs, NPs, PAs) from diverse clinics
* Review simulated patient cases with MASLD risk factors
* Use either usual care tools (standard labs and optional FIB-4 calculator) or FibroX (AI-generated risk score, triage band, and explainability panel)
* Make diagnostic and referral decisions for each case
* Complete surveys on usability, trust in AI, confidence, and cognitive workload
This study will help determine whether FibroX can be integrated into real-world primary care workflows to support earlier and more accurate detection of liver fibrosis and portal hypertension, potentially reducing missed diagnoses, unnecessary referrals, and improving patient outcomes.